Skip to main content
Themis Medicare Ltd. logo

Themis Medicare Ltd. — Investor Relations & Filings

Ticker · THEMISMED ISIN · INE083B01024 LEI · 335800LHRDVIKH69AF42 BSE.NS Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2026-05-28 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS THEMISMED

About Themis Medicare Ltd.

https://www.themismedicare.com/

Themis Medicare Ltd. is a research-driven pharmaceutical organization specializing in the development, manufacture, and marketing of a diverse range of therapeutic products. The company focuses on high-value segments including pain management, anesthesia, critical care, anti-infectives, and oncology. Its core competencies lie in the production of Active Pharmaceutical Ingredients (APIs) and complex finished dosage formulations, particularly injectables. Themis Medicare maintains a strong emphasis on Research and Development, operating state-of-the-art facilities that adhere to international quality standards such as WHO-GMP. Through strategic partnerships and a robust supply chain, the company serves both domestic and international markets, providing specialized medical solutions for hospital-based care and chronic disease management. Its portfolio includes proprietary delivery systems and differentiated generic products designed to improve patient outcomes.

Recent filings

Filing Released Lang Actions
1. Approved the Audited Standalone and Consolidated Financial Results for the quarter and year ended 31st March, 2026 together with the Report issued by the Statutory Auditors, M/s. Krishaan ....
Interim / Quarterly Report Classification · 85% confidence The document is a board meeting outcome submitted under SEBI LODR Regulation 30, announcing the Board’s approval of the audited standalone and consolidated financial results for the quarter and year ended 31 March 2026, including the full audited statements and auditor’s report. It is not merely a highlights‐only earnings release, nor is it a full annual report or proxy; rather it is a comprehensive financial report for an interim period (quarter ended) with substantive data, fitting the definition of an Interim/Quarterly Report. FY 2026
2026-05-28 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 88% confidence The document is an Official Stock Exchange filing under SEBI Regulation 30 disclosing audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, along with the Statutory Auditor’s report and detailed line-by-line financial statements. It is not merely a brief earnings highlight (so not ER), nor is it a full Annual Report (10-K), but rather a comprehensive periodic financial report containing substantive financial data. Therefore it fits the definition of an Interim / Quarterly Report (IR). FY 2026
2026-05-28 English
Themis Medicare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve Standalone and Consolidated ....
Regulatory Filings Classification · 85% confidence The document is an intimation under SEBI Listing Regulations about the date of a Board meeting to consider financial results and dividend recommendation. It does not itself contain financial results or attach a report, nor announce management changes. It is a regulatory announcement to the stock exchanges, fitting the general regulatory filings category.
2026-05-26 English
General Updates
Share Issue/Capital Change Classification · 92% confidence The document is an official disclosure sent to BSE/NSE under Regulation 30 of SEBI LODR, announcing board approval and in-principle approval application for preferential allotment of convertible warrants and enclosing a valuation report and compliance certificate. This is a corporate action involving a new share issue (preferential allotment of warrants), which falls under Share Issue/Capital Change.
2026-05-12 English
Please refer to the attachment.
Capital/Financing Update Classification · 78% confidence The document is a disclosure under SEBI Listing Regulations informing stock exchanges about the preferential allotment of convertible warrants – a financing/capital-raising activity. It provides a valuation report and updated compliance certificate in connection with that transaction. This falls under updates on company fundraising or capital structure changes (Capital/Financing Update).
2026-05-12 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter from Themis Medicare Limited addressed to stock exchanges (BSE and NSE) regarding a newspaper publication notice about a special window for re-lodgement of transfer requests and dematerialisation of physical shares. It references a SEBI circular and includes details about the publication in newspapers and availability on the company's website. The content is an announcement of a notice publication rather than the notice or report itself. The document is about informing the exchanges and public about the publication of a notice, not the notice content or a financial report. It is not a financial report, earnings release, management discussion, or any other detailed report type. It is also not a certification or insider dealing report. The document is relatively short and serves as an announcement for information and records. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and notification to exchanges about a publication related to share transfer procedures.
2026-04-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.